Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

$17.96 +1.70 (+10.46%)

Closing price 04:00 PM Eastern

Extended Trading

$17.77 -0.19 (-1.05%)

As of 08:00 PM Eastern

Sarepta Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 29 Analyst Ratings

Sell
5

Hold
16

Buy
8

Based on 29 Wall Street analysts who have issued ratings for Sarepta Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 29 analysts, 5 have given a sell rating, 16 have given a hold rating, and 8 have given a buy rating for SRPT.

Consensus Price Target

$48.80
171.71% Upside

According to the 29 analysts' twelve-month price targets for Sarepta Therapeutics, the average price target is $48.80. The highest price target for SRPT is $160.00, while the lowest price target for SRPT is $13.00. The average price target represents a forecasted upside of 171.71% from the current price of $17.96.

Get the Latest News and Ratings for SRPT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors.

SRPT Analyst Ratings Over Time

Type	Current Forecast 8/7/24 to 8/7/25	1 Month Ago 7/8/24 to 7/8/25	3 Months Ago 5/9/24 to 5/9/25	1 Year Ago 8/8/23 to 8/7/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	12 Buy rating(s)	17 Buy rating(s)	15 Buy rating(s)
Hold	16 Hold rating(s)	12 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	5 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$48.80	$60.88	$126.74	$187.72
Forecasted Upside	171.71% Upside	219.89% Upside	249.43% Upside	34.03% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

SRPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SRPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sarepta Therapeutics Stock vs. The Competition

Type	Sarepta Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.10	2.81	2.53
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	178.46% Upside	12,451.68% Upside	14.24% Upside
News Sentiment Rating	Neutral News See Recent SRPT News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/7/2025	The Goldman Sachs Group 3 of 5 stars	Salveen Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$19.00	+9.05%
8/7/2025	Wells Fargo & Company 3 of 5 stars	Yanan Zhu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$48.00 ➝ $50.00	+184.72%
7/29/2025	Barclays 3 of 5 stars	Gena Wang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$22.00	+26.32%
7/29/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
7/29/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Perform ➝ Market Perform	$25.00 ➝ $50.00	+198.56%
7/29/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $20.00	+44.30%
7/29/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Biren Amin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$15.00	+8.23%
7/29/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Sell
7/29/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	William Pickering Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00	-6.20%
7/29/2025	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Hartaj Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$30.00 ➝ $37.00	+166.96%
Get the Latest News and Ratings for SRPT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
7/29/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Anupam Rama Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$24.00	+73.16%
7/28/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gil Blum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform
7/24/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Tsai Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$40.00 ➝ $35.00	+220.42%
7/23/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
7/22/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Yigal Nochomovitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell ➝ Sell
7/21/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/21/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
7/21/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform
7/21/2025	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Uy Ear Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$40.00 ➝ $14.00	-0.50%
7/18/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
7/18/2025	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
7/17/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Perform ➝ Sector Perform	$25.00 ➝ $23.00	+7.19%
7/17/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Skorney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$30.00 ➝ $35.00	+90.42%
6/18/2025	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Baral Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00	+11.32%
6/17/2025	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
6/16/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Kluska Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
6/6/2025	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$80.00	+104.03%
5/8/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Clark-Gartner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline	$50.00	+36.17%
5/7/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Debjit Chattopadhyay Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$112.00 ➝ $98.00	+160.85%
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$150.00	+27.61%
2/29/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$224.00	+71.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:37 PM ET.

SRPT Forecast - Frequently Asked Questions

: According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Sarepta Therapeutics is $48.80, with a high forecast of $160.00 and a low forecast of $13.00.
: 29 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 5 sell ratings, 16 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SRPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SRPT, but not buy additional shares or sell existing shares.
: According to analysts, Sarepta Therapeutics's stock has a predicted upside of 171.71% based on their 12-month stock forecasts.
: Over the previous 90 days, Sarepta Therapeutics's stock had 10 downgrades and 4 upgrades by analysts.
: Sarepta Therapeutics has been rated by research analysts at Baird R W, Bank of America, Barclays, BMO Capital Markets, Cantor Fitzgerald, Citigroup, Deutsche Bank Aktiengesellschaft, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Sanford C. Bernstein, Scotiabank, TD Cowen, The Goldman Sachs Group, UBS Group, Wells Fargo & Company, William Blair, and Wolfe Research in the past 90 days.
: Analysts like Sarepta Therapeutics less than other "medical" companies. The consensus rating for Sarepta Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SRPT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:SRPT) was last updated on 8/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target